Literature DB >> 21045497

Tuberculous optochiasmatic arachnoiditis.

A Anupriya1, M Sunithi, T Maya, M Goel, M Alexander, S Aaron, V Mathew.   

Abstract

Arachnoiditis involving optic nerve and the optic chiasm can occur as a complication of tuberculous meningitis (TBM). This study evaluates the clinical features, cerebrospinal fluid (CSF) and laboratory parameters and imaging findings of optochiasmatic arachnoiditis (OCA) and also tried to identify any factors which can predict this complication in patients with TBM. Patients admitted with TBM in the neurology wards of a tertiary care teaching hospital over a period of 6 years formed the material for this study. Student's "t" test and univariate analysis were done to identify any predictors for this complication and the variables found to be significant were further analyzed by multivariate logistic regression analysis. One hundred sixty-three patients with TBM, admitted over a 6-year period, were studied. Twenty-three (14%) patients developed OCA. Eighteen out of 23 (78%) developed this complication while on antituberculous treatment (ATT) and 5/23 (22%) were newly diagnosed cases of TBM. Of those already on treatment, 12/23 (52%) were receiving only ATT, the remaining 6/23 (26%) had received steroids along with ATT in varying doses and duration. The average period from diagnosis of TBM to visual symptoms was 6.4 months. On the multivariate logistic regression analysis, female sex (P < 0.037), age less than 27 (P < 0.008) years and protein content in the CSF > 260 mg% (P < 0.021) were the factors predisposing toward this complication. At 6 months follow-up, on treatment with steroids and ATT, 17% had improvement and no further deterioration was noted in visual acuity in 52%. OCA can develop even while on treatment with ATT. Young women with a high CSF protein content seem to be more prone for this complication.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21045497     DOI: 10.4103/0028-3886.72194

Source DB:  PubMed          Journal:  Neurol India        ISSN: 0028-3886            Impact factor:   2.117


  9 in total

Review 1.  Neurotuberculosis: an update.

Authors:  Ajith Cherian; Kesi Chellappan Ajitha; Thomas Iype; K P Divya
Journal:  Acta Neurol Belg       Date:  2021-01-05       Impact factor: 2.396

2.  Tuberculomas in "Critical" Locations of the Visual Pathway-A Masquerader.

Authors:  Aastha Takkar; Karthik Vinay Mahesh; Ritu Shree; Julie Sachdeva; Sahil Mehta; Vivek Lal
Journal:  Neuroophthalmology       Date:  2017-08-09

Review 3.  The leptomeninges as a critical organ for normal CNS development and function: First patient and public involved systematic review of arachnoiditis (chronic meningitis).

Authors:  Carol S Palackdkharry; Stephanie Wottrich; Erin Dienes; Mohamad Bydon; Michael P Steinmetz; Vincent C Traynelis
Journal:  PLoS One       Date:  2022-09-30       Impact factor: 3.752

4.  Unusual fundus examination findings in tuberculous meningitis.

Authors:  Rajesh Verma; Tejendra S Chaudhari
Journal:  BMJ Case Rep       Date:  2013-02-08

Review 5.  Neuro-ophthalmic manifestations of tuberculosis.

Authors:  Rebika Dhiman; Subodh Lakra; Prateek Kumar Panda; Naren Hemachandran; Sanjay Sharma; Rohit Saxena
Journal:  Eye (Lond)       Date:  2021-06-14       Impact factor: 3.775

6.  Tuberculous optochiasmatic arachnoiditis.

Authors:  Rajesh Verma; Tushar B Patil; Rakesh Lalla
Journal:  J Glob Infect Dis       Date:  2014-04

7.  Management of paradoxical response in pediatric tubercular meningitis with methylprednisolone.

Authors:  Nitin Nema; Abha Verma; Kuldeep Singh; Virendra Mehar
Journal:  Middle East Afr J Ophthalmol       Date:  2014 Apr-Jun

8.  Clinical Spectrum of Central Nervous System Tuberculosis and the Efficacy of Revised National Tuberculosis Control Program in its Management.

Authors:  E Uma Maheswari; R M Bhoopathy; K Bhanu; Heber Anandan
Journal:  J Neurosci Rural Pract       Date:  2019 Jan-Mar

9.  Medical management of acute loss of vision in tuberculous meningitis: A case report.

Authors:  Maryam Amour; Sarah Shali Matuja; Jerome H Chin
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2020-01-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.